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Abstract
Several mutations in α4 or β2 nicotinic receptor subunits are linked to autosomal dominant
nocturnal frontal lobe epilepsy (ADNFLE). One such missense mutation in the gene encoding the
β2 neuronal nicotinic acetylcholine receptor (nAChR) subunit (CHRNB2) is a valine-to-leucine
substitution in the second transmembrane domain at position 287 (β2VL). Previous studies
indicated that the β2VL mutation in mice alters circadian rhythm consistent with sleep alterations
observed in ADNFLE patients (Xu et al., 2011). The current study investigates changes in
nicotinic receptor function and expression that may explain the behavioral phenotype of β2VL
mice. No differences in β2 mRNA expression were found between wild-type (WT) and
heterozygous (HT) or homozygous mutant (MT) mice. However, antibody and ligand binding
indicated that the mutation resulted in a reduction in receptor protein. Functional consequences of
the β2VL mutation were assessed biochemically using crude synaptosomes. A gene-dose
dependent increase in sensitivity to activation by acetylcholine and decrease in maximal nAChR-
mediated [3H]-dopamine release and 86Rb efflux were observed. Maximal nAChR-mediated [3H]-
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GABA release in the cortex was also decreased in the MT, but maximal [3H]-GABA release was
retained in the hippocampus. Behaviorally both HT and MT mice demonstrated increased
sensitivity to nicotine-induced hypolocomotion and hypothermia. Furthermore, WT mice display
only a tonic-clonic seizure (EEG recordable) 3 min after injection of a high dose of nicotine, while
MT mice also display a dystonic arousal complex (non-EEG recordable) event 30 s after nicotine
injection. Data indicate decreases in maximal response for certain measures are larger than
expected given the decrease in receptor expression.
Keywords
nicotinic acetylcholine receptor; autosomal dominant nocturnal frontal lobe epilepsy; nicotine;
autoradiography; knock-in mouse; synaptosomes
1. Introduction
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a form of familial
monogenic epilepsy marked by partial seizures that include rhythmic and repetitive limb
movements, dystonic posturing, and rapid uncoordinated movements during phase II of non-
REM sleep (Steinlein, 2010). Some ADNFLE patients carry mutations in the CHRNA4,
CHRNB2 or CHRNA2 genes, which encode the nicotinic acetylcholine receptor (nAChR)
α4, β2, and α2 subunits respectively (Aridon et al., 2006; Bertrand et al., 2005; De Fusco et
al., 2000; Hirose et al., 1999; Phillips et al., 2001; Steinlein et al., 1997; Steinlein et al.,
1995). The clinical phenotypes appear indistinguishable among patients with different
mutations (Combi et al., 2004). The human mutations have quite high penetrance for
ADNFLE (De Fusco et al., 2000; Phillips et al., 1995)
Several mutations have been elucidated in the α4β2*-nAChR of ADNFLE patients (*
indicates possible presence of additional subunits). Several are in the channel-lining second
transmembrane (M2) domain of the α4 subunit (S247F, S252L, and 776ins3); while other
mutations are located in the M2 domain of the β2 subunit, including V287L and V287M
(Bertrand et al., 2005; Combi et al., 2004; De Fusco et al., 2000; Oldani et al., 1998; Phillips
et al., 2001; Steinlein et al., 1997). ADNFLE mutations in α4β2*-nAChR result in increased
sensitivity to acetylcholine, leading to a receptor gain-of-function. This increase agonist
sensitivity has been postulated to contribute to a lowered seizure threshold consistent with
an epilepsy phenotype (Bertrand et al., 2002; Fonck et al., 2005; Klaassen et al., 2006).
Furthermore, genetic deletions of the α4 or β2 subunits in mice do not result in spontaneous
seizures or any form of nicotine-induced phenotype typical of ADNFLE (McCallum et al.,
2006; Picciotto et al., 1998; Tritto et al., 2004).
The β2V287L (β2VL) mutation was first identified in a family in which all eight affected
members had the mutant gene (DeFusco et al., 2000), However, the mutation showed
incomplete penetrance as four unaffected members also carried the β2VL mutation. In vitro
studies in oocytes or cell lines transfected with the subunits of interest have demonstrated
the impact of this mutation on receptor function. HEK293 cells transfected with α4β2-
nAChR harboring the β2VL missense mutation displayed a considerably slower rate of
desensitization as compared to wild-type α4β2 receptors (De Fusco et al., 2000). The same
β2VL mutation reduced the Ca2+ dependent potentiation of the acetylcholine response in
α4β2-nAChR (Rodrigues-Pinguet et al., 2003).
Two different mouse models of ADNFLE have been generated using the β2VL mutant gene.
One was made by transgene insertion resulting in three lines with varying copy number
(Manfredi et al., 2009). Mice with higher copy number display an epileptic phenotype, as
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measured by continuous 24 hour EEG; more seizures were seen in the higher copy number
lines while the line with low expression did not have seizures. Consistent with ADNFLE in
humans, the seizures occurred predominately during the sleep phase and mostly during
periods of increased delta wave activity. However, numbers of receptors did not change with
expression of the mutation. Another model of the β2VL mutation is a knock-in mouse,
which has an altered activity-rest cycle, as well alterations in anxiety behaviors (Xu et al.,
2011). These mice are also more sensitive to nicotine-induced convulsions, especially the
milder signs including Straub tail (Xu et al., 2011). Spontaneous seizures were rarely
observed, but mutant mice did have a higher mortality rate, possibly because of unobserved
seizures.
This knock-in mouse provides a model to investigate whether this mutation alters expression
or function of β2*-nAChRs in an animal, and whether these alterations result in behavioral
changes. In the current study, β2VL knock-in mice were studied for the effects of this
mutation on behavioral and physiological traits affected by nicotine in wild-type mice. In
addition, the effects of the β2VL mutation on β2 mRNA expression, nAChR numbers and
nAChR-mediated synaptosomal function were assessed in multiple brain regions.
2. Methods
2.1. Materials
The radioisotopes [3H]-dopamine (7,8-3H at 30–50 Ci/mmol), [3H]-GABA (2,3-3H at 35 Ci/
mmol), α[35S]-UTP (1250 Ci/mmol), [125I]-epibatidine (2200 Ci/mmol), and carrier-
free 86RbCl (initial specific activity 13.6–18.5 Ci/μg)were purchased from Perkin Elmer
(Waltham, MA). α-Conotoxin MII (α-CtxMII) and [125I]-α-CtxMII were prepared as
described previously (Cartier et al., 1996; Whiteaker et al., 2000b). NaCl, KCl, CaCl2,
MgSO4, glucose, sucrose, HEPES, tetrodotoxin, (−) nicotine bitartrate, (−)-nicotine free
base, acetylcholine iodide (ACh), diisopropyl fluorophosphate (DFP), polyethelenimine,
bovine serum albumin (BSA), and cytisine were purchased from Sigma Chemical Co (St.
Louis, MO). Normal rat serum and protease free bovine serum albumin were purchased
from Jackson ImmunoResearch (West Grove, PA).
2.2. β2VL Mice
Knock-in mice were generated using a mixed BALB6/C57B6 background (Xu et al., 2011)
and were obtained from Dr. Stephen Heinemann at the Salk Institute. Mice were bred at the
Institute for Behavioral Genetics, Boulder, CO. Lights were maintained on a 12 h light/dark
cycle with lights on at 7am. Animal care and experimental procedures were performed in
accordance with the guidelines and with the approval of the Animal Care and Utilization
Committee at the University of Colorado, Boulder. Upon weaning, tail clippings were
obtained for genotyping as described (Xu et al., 2011). Mice were housed with like-sexed
littermates and allowed access to food and water ad libitum. Wildtype β2VL mice (β2
287VV, WT), heterozygous (β2 287VL, HT), and mutant (β2 287LL, MT) mice were
assessed.
2.3. Tissue preparation for autoradiographic ligand binding and in situ hybridization
Following cervical dislocation and decapitation, whole brains were rapidly frozen in
isopentane (−35°C, 10 s) and stored at −70°C until sectioning. Coronal sections (14 μM
each) were obtained using an IEC (International Equipment Corp, Needham Heights, MA)
or Leica CM 1850 cryostat/microtome (Nusslock, Germany) and thaw mounted onto
SuperFrost slides (Fisher Scientific, Pittsburgh, PA). Nine sets of serial sections were
obtained so that ligand binding and in situ hybridization could be performed in each mouse.
Sections were desiccated and stored at −70°C until use.
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2.4. In situ hybridation for β2 subunit mRNA
The distribution of β2 mRNA expression was determined using in situ hybridization with
radiolabeled riboprobes as previously described (Marks et al., 1992). The β2 subunit probe
was synthesized from HindIII linearized pSP65-49 using Sp6 RNA polymerase with α
[35S]-UTP as the sole source of UTP. Tissue was fixed by immersion in 4%
paraformaldehyde in phosphate buffered saline for 15 min, washed, acylated by incubation
with acetic anhydride and dehydrated with an ethanol series before air drying and vacuum
storage. β2 nAChR subunit probe (100 μL, 5 × 106 cpm/ml) in hybridization solution (50%
formamide, 10% dextran sulphate, 300mM NaCl, 10mM Tris, 1mM EDTA, 500 μg/mL
yeast tRNA, 10mM DTT, 1X Denhardt’s solution, pH 8.0) was applied to each slide.
Hybridization was performed at 58°C for 18 hrs. Following the hybridization, sections were
washed 4 times in 4X SSC (1X SSC, NaCl, 150 mM: sodium citrate, 6 mM; pH = 7.0)
incubated for 30 min with RNase A (20μg/mL), washed with 2X SSC/1mM DTT (three
times), 1X SSC/1mM DTT and 0.5X SSC/1mM DTT to desalt the samples. Slides were then
subjected to a high stringency wash with 0.1X SSC/1mM DTT at 60°C for 30 min.
Following dehydration with an ethanol series, samples were exposed for 5 days Kodak
BioMax film.
2.5. [125I]-mAb 270 Labeling
125I-mAb autoradiography was performed as previously detailed (Whiteaker et al., 2006).
Sections were allowed to equilibrate to room temperature and then rehydrated for 15 min in
PBS buffer (100mM NaCl and 10 mM NaPO4, pH 7.5). Sections were then incubated in
humidified chambers at 4°C for 48 hours with 0.3 nM 125I-mAb 270 in PBS with 10 mM
NaN3, 10% (v/v) normal rat serum, and 5% (w/v) protease-free bovine serum albumin.
Sections were then washed 4 times in PBS for 30 min each at 22°C, air dried and desiccated
overnight under vacuum prior to exposure to Kodak Biomax film for 5 days.
2.6. [125I]-Epibatidine autoradiography
[125I]-Epibatidine binding was conducted as previously described (Whiteaker et al., 2000a).
Coronal sections were incubated in binding buffer (NaCl, 140 mM; KCl, 1.5 mM; CaCl2, 2
mM; MgSO4, 1 mM; bovine serum albumin, 1g/L; HEPES buffer, pH 7.5, 25 mM)
containing 500 pM [125I]-epibatidine for 2 h at 22° C. Final specific activity of 110 Ci/mmol
was obtained by diluting [125I]-epibatidine (2200 Ci/mmol) with unlabeled 6I-epibatidine.
As [125I]-epibatidine binds with high affinity to multiple nAChR, differential inhibition with
cytisine (50 nM) was used to distinguish between cytisine-sensitive and cytisine-resistant
binding sites. Non-specific binding was determined using 100 μM (−) nicotine bitartrate.
Following wash with ice-cold solutions twice with binding buffer (15 s each), twice with
0.1xbinding buffer (5 s each) and twice with 25 mM HEPES, pH=7.5 (5 s each)], sections
were air dried and desiccated overnight under vacuum and subsequently exposed to Kodak
BioMax for 5 days.
2.7. [125I]-α-CtxMII autoradiography
[125I]-α-CtxMII binding was performed as previously described (Whiteaker et al., 2000b).
Sections were incubated in binding buffer for 10 min (as described in [125I]-epibatidine
autoradiography) with minor modifications (the addition of 1 mM phenylmethylsulfonyl
fluoride (PMSF) and deletion of bovine serum albumin). Sections were then incubated in 0.5
nM [125I]-α-CtxMII in binding buffer with the addition of the protease inhibitors leupeptin,
pepstatin, and aprotinin (10 μg/ml each) for 2 h at 22° C. Slides were subsequently washed
in ice-cold protein free binding buffer twice for 30 s followed by two 10 s washes in 0.1x
protein free binding buffer. Final rinses (2 × 5 s each) were conducted in ice-cold 5 mM
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HEPES, pH 7.5. Sections were subsequently air dried and desiccated overnight prior to
exposure to Kodak MR film for 5 days.
2.8. Quantitation of autoradiography
Following exposure to the Kodak BioMax film, each set of samples was exposed to Super
Resolution Phosphor storage screens, Type SR (Perkin Elmer Life Sciences) for 2–4 days.
Images were collected using a Packard Cyclone Phosphor Imaging system (Perkin Elmer
Life Sciences). Tissue paste samples containing measured amounts of either 125I or 35S were
included with each set of samples to establish standard curves. Signal intensity was
quantified using OptiQuant software. A minimum of five measurements were recorded for
each brain region analyzed for each animal and the mean of all measures for each region
was used for further analysis. Nonspecific hybridization or binding was determined using
sections from β2 knockout mice, which do not exhibit any detectable, specific radioactive
signal. Regions were identified with reference to a mouse brain atlas (Franklin Keith B. J.
and Paxinos, 1997).
2.9. Agonist-stimulated 86Rb+ efflux
Agonist-stimulated 86Rb+ efflux from crude preparations of thalamic and cortical
synaptosomes of wildtype (WT), heterozygous (HT) and homozygous mutant (MT) mice
were measured as previously described (Marks et al., 1999). Adult mice were killed by
cervical dislocation and thalamus (Th) (excluding medial habenula) and cortex (Cx) were
dissected on an ice-cold platform. Tissue was homogenized in 1 ml of ice cold 0.32 M
sucrose solution buffered to pH 7.5 using 5 mM HEPES with a glass/Teflon tissue grinder.
A crude synaptosomal pellet was obtained following centrifugation at 10,000 × g for 20 min
at 4°C. Cortical and thalamic crude synaptosomal pellets were resuspended in 0.8 ml and
0.35 ml load buffer (in mM; 140 NaCl, 1.5 KCl, 2 CaCl2, 1 MgSO4, 25 HEPES, and 22
glucose, pH = 7.5), respectively, and maintained on ice until incubation with 86Rb+.
Synaptosomes were incubated with 4 μCi 86Rb+ for 30 min at ambient temperature. To
inhibit acetylcholinesterase activity, 10 μM diisopropyl fluorophosphate was added during
the final 5 min of uptake. Uptake was terminated by filtration of the sample onto a 6 mm
diameter glass fiber filter (Type AE; Pall Life Sciences, Port Washington, NY) under gentle
vacuum (0.8 atmospheres) followed by one wash of 0.5 ml load buffer.
Filters containing the crude synaptosomes loaded with 86Rb+ were transferred to a
polypropylene stage and superfused with buffer (in mM; 135 NaCl, 1.5 KCl, 5 CsCl, 2
CaCl2, 1 MgSO4, 25 HEPES, 22 glucose, 50 nM tetrodotoxin, 1 μM atropine, and 0.1%
bovine serum albumin) via a peristaltic pump at a flow rate of 2 ml/min. A second peristaltic
pump set at a 3 ml/min flow rate (to prevent pooling of buffer on the stages) pumped
superfusate through a Cherenkov cell and into a β-Ram detector (Lab Logic, Brandon, FL).
Radioactivity was evaluated for 3 min with a 3 s detection window for each superfusion.
Crude synaptosomes were exposed to acetylcholine or nicotine for 5 sec to elicit nAChR
mediated 86Rb+ efflux. Concentration effect curves were generated by varying the agonist
concentrations.
To evaluate the effect of previous nicotine exposure (steady-state desensitization) on ACh-
stimulated 86Rb+ efflux, thalamic and cortical samples were superfused for 8 min with
buffer containing nicotine prior to a 5 s stimulation with ACh. WT crude synaptosomes were
exposed to 0, 1, 3, 10, 30, or 100 nM nicotine. HT and MT samples were treated with 0, 0.1,
0.3, 1, 3, or 30 nM nicotine. After nicotine pre-exposure, all crude synaptosomes were
exposed to 10 μM ACh for 5 s.
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2.10. [125I]-Epibatidine binding to membrane fragments
Besides measuring receptor expression in intact mouse brain sections using [125I]-
epibatidine binding, we also used [125I]-epibatidine binding to measure nAChR expression
in the synaptosomal membranes. [125I]-Epibatidine binding followed previously published
methods (Whiteaker et al., 2000a). Frozen, washed pellets were resuspended in hypotonic
buffer and centrifuged at 20,000 × g for 20 min. The resulting pellets were then resuspended
in ice-cold water, with volume adjusted such that <10% of the [125I]-epibatidine was bound
to the protein at the highest ligand concentration. Samples were incubated for 3 h at ambient
temperature in 96-well polystyrene plates at a final volume of 30 μl of binding buffer
containing 400 pM 125I-epibatidine. Following incubation, samples were diluted with 200 μl
ice-cold wash buffer. The diluted samples were then filtered through glass fiber filters (top-
MFS type B; bottom- Gelman A/E) treated with 0.5% polyethelenimine under 0.2-
atmosphere vacuum using a Inotech Cell Harvester (Inotech Systems, Rockville, MD) and
washed with ice-cold buffer five times. Sample radioactivity was measured at 80%
efficiency by a Packard Cobra Auto Gamma Counter (Packard Instruments, Downers Grove,
IL). Total protein concentration was determined using the method of Lowry utilizing bovine
serum albumin standards (Lowry et al., 1951).
2.11. [3H]-Dopamine uptake and release
[3H]-Dopamine release was measured as previously described (Salminen et al., 2007;
Salminen et al., 2004). For uptake of [3H]-dopamine, crude synaptosomes were incubated at
37° in uptake buffer (containing the following, in mM, 128 NaCl, 2.4 KCl, 3.2 CaCl2, 1.2
KH2PO4, 1.2 MgSO4, 25 HEPES, pH 7.5, 10 glucose, 1 ascorbic acid, and 0.01 pargyline)
for 10 min before addition of 100 nM [3H]-dopamine (1 μCi for every 0.2 ml of
synaptosomes) and diisopropyl fluorophosphate (10 μM), and the suspension was incubated
for an additional 5 min. Aliquots of crude synaptosomes (80 μl) were distributed onto filters
and superfused with buffer (uptake buffer containing 0.1% bovine serum albumin, 1 μM
nomifensine and 1 μM atropine) at 0.7 ml/min for 10 min. For experiments using α-
conotoxin MII (α-CtxMII) to inhibit the α6β2*-nAChR, crude synaptosomes were exposed
to α-CtxMII (50 nM) for the last 5 min of the 10 min buffer superfusion. This concentration
of α-CtxMII inhibits all α6β2*-nAChR subtypes present in the mouse striatum (Salminen et
al., 2007). After buffer and/or α-CtxMII superfusion, crude synaptosomes were exposed to
ACh for 20s. Basal and ACh-stimulated release was determined by collecting 23 10-s
fractions into 96-well plates.
2.12. [3H]-GABA uptake and release
Uptake is similar to [3H]-dopamine, as described above, with modifications (Lu et al., 1998;
McClure-Begley et al., 2009). Ascorbate and pargyline were omitted from the uptake buffer
and 1.25 mM aminooxyacetic acid was added. A 16 s exposure to ACh or 20 mM K+
followed incubation with [3H]-GABA (8 μCi in 0.8 ml). Superfusion buffer without
nomifensine and containing NO-711 (100 nM) was used. Samples were processed as
described in DA release above.
2.13. Evaluation of nicotine sensitivity in β2VL mice
All nicotine doses are expressed as free base. Behavioral test measures were selected based
on previous studies (Marks et al., 1985; Tritto et al., 2004). Mice were habituated to the
experimental room for one h prior to testing. Following the acclimation period, mice
received a single intraperitoneal injection of nicotine (WT 0.0, 0.25, 0.50, 1.0, or 1.5 mg/kg;
HT and MT 0.0, 0.125, 0.25, 0.50 or 1.0 mg/kg). Mice were placed in a Y-maze apparatus 3
min after nicotine injection and assessed thereafter for 3 min. Immediately following Y-
maze assessment, mice were placed in a bright light open field and assessed for 5 min.
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Following completion of the open field test, mice were singly-housed in a cage until
temperature was measured fifteen min post injection.
2.14. Electroencephalographic (EEG) recordings
Electrode-implant surgeries and EEG recordings were performed as described (Fonck et al.,
2005). Mice were implanted with cortical screw electrodes seven days before the start of
experiments. General anesthesia was induced with a ketamine (98 mg/kg)/xylazine (10 mg/
kg) mixture delivered intraperitoneally. Bilateral screw electrodes were stereotactically
inserted in the parietal cortex or the primary motor cortex, with a third electrode serving as
ground. Stereotactic coordinates are expressed in millimeters, with the first number
indicating anterior-posterior placement from Bregma and the second number representing
lateral placement from midline: 2 ± 1.7 for primary motor cortex M1 and 0.8 ± 1.2 for
primary somatosensory cortex. Simultaneous video and EEG recordings started 15 min
before and continued for 15 min after a single nicotine injection (5 mg/kg, i.p.). Data were
acquired with a differential amplifier (Brownlee Precision, San Jose, CA), with a 1 kHz
sampling rate and band-pass filtered a 1–200 Hz. EEG data were analyzed with Clampfit 8.2
software (Molecular Devices, Sunnyvale, CA). All EEG traces were examined for evidence
of spike-wave, interictal spikes, or other wave forms demonstrating ictal activity.
2.15. Dystonic arousal complex (DAC) assay
Mice were moved into the test room and weighed 24 h prior to the experiment. To test for
DAC-related behaviors, β2VL MT and WT mice were injected with 2 mg/kg of nicotine
(i.p.). After the injections, the mice were placed in an elevated rectangular platform (30 × 43
cm, 1.3 m above the floor) covered with white countertop paper and video recorded for 5
min. Nineteen homozygous β2VL MT mice and an equal number of WT littermates were
used. The mice were age-matched, 2–5 month-old males. The DAC encompasses a number
of stereotypic behaviors including (1) jerky, darting head and body movements, (2) forelimb
dystonia (tonic forelimb extension and tonic digit splaying), and (3) diagonal retrograde tail
(Straub tail) (Teper et al., 2007). In the current study, WT and β2VL MT mice were scored
for diagonal retrograde tail, tonic forelimb extension, tonic splaying of the forelimb digits,
as well as for forelimb clonus. Diagonal retrograde tail was defined as a bending of the tail >
135° from its natural horizontal position (Teper et al., 2007). The mice were not scored for
jerky, darting movements because this behavior was less well defined than the other
behaviors. All scoring was done by an observer blinded to genotype.
2.16. Data analysis
The SPSS statistical package was used for all ANOVAs. The non-linear least squares curve
fitting program in SigmaPlot was used to fit dose-response relations for behavioral data or
concentration-effect relations for biochemical data. The Fisher exact test was used to test
DAC data for significant differences between the occurrence of the behaviors in MT and
WT mice.
Autoradiographic data were initially measured as signal density (pixels/mm2) from images
collected using the Packard Cyclone Storage Phosphor Screen analyzer and subsequently
converted to cpm/mg tissue using the standard curves for either 125I or 35S included on each
phosphor screen. For ligands with known specific activity, signals densities were converted
to fmol/mg tissue. Results were subsequently analyzed by two-way ANOVA with genotype
and brain region as the independent variables. The effect of genotype on signal intensity
within each brain region was subsequently examined by one-way ANOVA. Where
appropriate, Dunnett’s post hoc test was applied.
O’Neill et al. Page 7
Pharmacol Biochem Behav. Author manuscript; available in PMC 2014 January 01.
$watermark-text
$watermark-text
$watermark-text
The effect of genotype on concentration-response relations measured by 86Rb+ efflux was
evaluated by curve-fitting data to a model with two Michaelis-Menten equations to calculate
the components with higher sensitivity (HS) and lower sensitivity (LS) to activation by ACh
as follows:
where V is the total 86Rb+ efflux measured at each [ACh], Vmax,HS and Vmax,LS are the
estimated maximal responses elicited by the HS and LS components, respectively, with
EC50 values ([ACh] eliciting half maximal efflux) of EC50,HS and EC50,LS, for the HS and
LS components, respectively. Kinetic parameters were subsequently analyzed using one-
way ANOVA followed by Dunnett’s post hoc test.
The concentration-response relations for ACh-stimulated neurotransmitter release
([3H]dopamine and [3H]GABA) and nicotine-stimulated 86Rb+ efflux were adequately fit
using the Michaelis-Menten equation:
Where V is the agonist-stimulated neurotransmitter release at each [Ag], Vmax is the
estimated maximal release and EC50 the concentration of ACh eliciting half-maximal
response. The effects of genotype on Vmax and EC50 were subsequently analyzed using one-
way ANOVA followed by Dunnett’s post hoc test.
The effects of the β2VL genotype on ACh-stimulated response were analyzed two ways: 1)
Two-way ANOVAs examining the effect of ACh concentration and β2 genotype and 2)
least squares curve fitting of the data to calculate the Emax and EC50.
The parameters for the curves for the steady-state desensitization of ACh-stimulated 86Rb+
efflux by prior exposure to nicotine were calculated using the following equation:
where Vnic is the efflux measured after exposure to each nicotine concentration, [nic], Vinh
is the maximum efflux inhibited by exposure to nicotine, DC50 is the apparent concentration
of nicotine eliciting 50% desensitization, and Vrem is the efflux insensitive to inhibition.
The locomotor activity and body temperature data were analyzed using two-way ANOVA
with genotype and nicotine dose as the independent variables. Subsequently one-way
ANOVA was used to compare the responses of mice varying in β2 genotype at each nicotine
dose. Results of the locomotor activity and hypothermia measures were also subjected to
least squares curve fitting using the following general equation to provide an estimate of the
effect of genotype on the EC50 for nicotine:
where the behavioral response is either the activity or temperature measured at each nicotine
dose, (nic), and the ED50 is the nicotine dose eliciting a 50% reduction in response. The
baseline response was measured following saline injection. For hypothermia, this equation
was modified to include a residual value for the calculation of ED
−2° (dose to elicit a
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temperature decrease of 2°C) to reflect the fact that a maximal temperature of 6° C is
achieved for HT and MT mice and of 4°C for WT mice.
3. Results and Discussion
3.1. Autoradiographic analysis of the expression of β2 mRNA, β2 protein, and ligand
binding sites
3.1.1. Autoradiographic illustration of the results of the β2VL mutation—The
autoradiograms shown in Figure 1 (for rows one through four, at the level of the thalamus,
approximately −2.1 Bregma; for the fifth row, at the level of the striatum, approximately
+0.02 Bregma) and Figure 2 (at the level of the IPN, approximately −3.3 Bregma) compare
the in situ hybridization for 35S labeled β2 mRNA (first row in each figure), [125I]-mAb270
labeling for β2 protein (second row), total binding for [125I]-epibatidine (third row),
cytisine-resistant [125I]-epibatidine binding (fourth row), and [125I]-αCtxMII binding (fifth
and final row) for WT, HT and MT β2VL mice.
3.1.2. No significant changes in β2 mRNA expression were observed as a
result of the β2VL mutation
3.1.2a. β2 mRNA expression-Results: We measured expression of β2 mRNA by in situ
hybridization with quantitative autoradiography. Fifteen brain regions were quantitated from
4 mice of each genotype. Signal intensity is summarized in Table 1. The expression of β2
mRNA differed among the brain regions (F14,135 = 77.2, p<0.001). Very high signal was
noted in medial habenula, with relatively high signals observed in the interpeduncular
nucleus, thalamus and dorsolateral geniculate nucleus. Cortical regions, olfactory tubercles
and striatum displayed lower hybridization. No significant differences were seen across
genotype (F2,135 = 1.81, p>0.05) for β2 subunit mRNA: average signal intensity was 107%
of control for HT mice and 99% of control for MT mice (Figure 3a).
3.1.2b. β2 mRNA expression-Discussion: The β2VL mutation did not affect mRNA
encoding the β2 subunit measured by in situ hybridization. Our observation is consistent
with the lack of effect of this mutation on β2 mRNA expression measured with rtPCR (Xu
et al., 2011) Retention of mRNA expression for this single-point contrasts with the gene-
dose dependent decrease in expression that occurs following deletion of the β2 nAChR gene
(Picciotto et al., 1995; Whiteaker et al., 2006). β2 mRNA expression is also altered by the
introduction of multiple copies of the β2VL gene in transgenic mice, in which differential
expression of the mutant transgene was observed among the three lines that were generated
(Manfredi et al., 2009). These observations indicate that number of copies of a gene can
change mRNA expression, but single-point mutations within the gene do not.
3.1.3. Overall [125I]-mAb270 binding is decreased as a result of the β2VL
mutation
3.1.3a. [125I]-mAb270 binding-Results: We then measured β2*-nAChR subunit protein by
binding of the β2-selective monoclonal antibody, [125I]-mAb 270 (Whiteaker et al., 2006;
Whiting and Lindstrom, 1987) autoradiographically (Swanson et al., 1987; Whiteaker et al.,
2006). The effects of the β2VL mutation on sixteen regions were quantitated from 4 mice of
each genotype. Binding of [125I]-mAb 270 varied significantly among brain regions
(F15,144=41.44, p<0.001). IPN had the highest level of [125I]-mAb 270 binding. High
binding was also measured in the geniculate nuclei, superior colliculus and thalamus.
Relatively lower binding was observed in olfactory bulbs, cortex, olfactory tubercles, and
inferior colliculus. An overall significant main effect of genotype on [125I]-mAb 270
binding was also detected (F2,144=7.12, p<0.01): the β2VL mutation decreased β2 receptor
protein levels. Overall the decrease was confined to MT mice (Figure 3b, average binding
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84% of control) with no change observed for HT mice (104% of control). Subsequent one-
way ANOVA analysis was performed on 16 regions, the results of which are shown in Table
2. While genotype had a significant effect overall, when analyzed by region [125I]-mAb 270
binding levels were decreased only in MT medial geniculate as compared to WT mice
(F2,9=5.088, p<0.05).
3.1.3b. [125I]-mAb270 binding-Discussion: This modest decrease in subunit expression as
a consequence of the β2VL mutation contrasts with the gene-dose dependent decrease
observed following deletion of the β2 subunit (Picciotto et al., 1995; Whiteaker et al., 2006).
However, β2 nAChR subunit protein levels were higher in mice expressing multiple copies
of the β2 V289L transgene and this increase in protein reflected the increase in mRNA
among the lines (Manfredi et al., 2009). However, the increase in β2 nAChR subunit protein
was not accompanied by a parallel increase in α4 nAChR subunit protein, indicating that the
elevated expression of β2 nAChR protein does not markedly affect expression of the
primary partner for the assembly of nAChR in the brain.
3.1.4. Overall [125I]-epibatidine binding is decreased as a result of the β2VL
mutation
3.1.4a. Cytisine-sensitive [125I]-epibatidine binding-Results: We then assessed [125I]-
epibatidine binding autoradiographically to evaluate the effects of the β2VL mutation on
ligand binding to nAChR. We measured total high-affinity [125I]-epibatidine binding and
[125I]-epibatidine binding in the presence of 50 nM cytisine (cytisine-resistant). This
concentration of cytisine has been previously shown to inhibit radiolabeled epibatidine
binding primarily to α4β2*-nAChR sites (Baddick and Marks, 2011; Champtiaux et al.,
2002; Marks et al., 2007) Therefore, cytisine-sensitive binding is a measure primarily of
α4β2*-nAChR, and is either the total binding in regions with no measurable cytisine-
resistant binding (discussed below), or the difference between total and cytisine-resistant
binding (non-α4β2*-nAChR including α6β2*-, α3β2*- and α3β4*-nAChR).
We quantitated 21 regions from 4 mice of each genotype for cytisine-sensitive binding
(Table 3). Cytisine-sensitive [125I]-epibatidine binding varied significantly among the brain
regions (F20,180 =23.84, p<0.001). Similar to the pattern observed for [125I]-mAb 270
binding, IPN had the highest level of cytisine-sensitive [125I]-epibatidine binding with high
binding also measured in the geniculate nuclei, superior colliculus and thalamus. Binding
was relatively lower in cortex, olfactory tubercles, striatum, inferior colliculus and
hippocampus. A significant main effect of genotype was also noted (F2,189 = 9.63, p<0.001).
As shown in Figure 3c, overall (excluding IPN and medial habenula) binding in HT mice
was 77% of control and in MT mice was 53% of control. Although [125I]-epibatidine
binding in HT and MT mice tends to be lower than binding in WT, only four regions, two
thalamic areas, the ventral tegmental nucleus, and the hypothalamus were statistically
different from WT by one-way ANOVA.
3.1.4b. Cytisine-sensitive [125I]-epibatidine binding-Discussion: Reduction in binding site
density following introduction of gain of function mutations has also been noted for mice
harboring the nAChR α4L9’S (Fonck et al., 2003), α4L9’A (Fonck et al., 2005) and
α4S248F (Teper et al., 2007) mutations. This pattern of steady-state receptor expression is
consistent with a downregulation in response to constant activation by low levels of
endogenous ACh that serves to reduce the impact of hyperactive receptors. The reduction in
ligand binding could also have resulted in the death of neurons harboring the mutation.
However, the observations that the MT mice expressed normal levels of β2 mRNA and
showed no obvious anatomical changes indicate that extensive cell death is unlikely.
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3.1.4c. Cytisine-resistant [125I]-epibatidine binding-Results: Cytisine-resistant [125I]-
epibatidine binding was measured in nine regions (Table 4). In the presence of cytisine, a
diverse set of [125I]-epibatidine binding sites is labeled (Baddick and Marks, 2011). This
population in the IPN, medial habenula and inferior colliculus contains primarily α3β4*-
nAChR sites, while in the remaining regions a fraction of this binding is due to α6β2*-
nAChR sites. Binding in interpeduncular nucleus and medial habenula is much higher than
that in any other region and this is reflected by the significant main effect of brain region
(F6,63 = 27.19, p<0.001). No overall effect of genotype was detected (F2,63 = 1.28, p>0.05).
As shown in Figure 3d, in the three regions where the α3β4*-nAChR subtype is
predominant, binding in the HT mice was 93% of control and that of MT mice was 117% of
control. No individual brain region displayed significantly changed cytisine-resistant [125I]-
epibatidine binding as a result of the β2VL mutation (One-way ANOVA).
3.1.4d. Cytisine-resistant [125I]-epibatidine binding-Discussion: As cytisine-resistant
[125I]-epibatidine binding primarily measures α3β4*-nAChR sites, (Baddick and Marks,
2011; Marubio et al., 1999; Zoli et al., 1998) it is not surprising this measure was unaffected
by the β2VL mutation.
3.1.5. [125I]-α-CtxMII binding is decreased as a result of the β2VL mutation—
We also assessed the effect of the β2VL mutation on α6β2*-nAChR and α3β2*-nAChR
sites autoradiographically by measuring [125I]-α-CtxMII binding (Champtiaux et al., 2002;
Whiteaker et al., 2002).
3.1.5a. [125I]-α-CtxMII binding-Results: Eleven regions were quantitated, with data
shown in Table 5. There was a significant main effect of brain region (F10,99 = 444.7,
p<0.001) reflecting the 5-fold difference in binding among the brain regions. Dorsolateral
and ventrolateral geniculate nuclei and superior colliculus had the highest binding site
density, while olfactory tubercles, ventral tegmental area and substantia nigra had the lowest
density. It should be noted that, while [125I]-α-CtxMII binding sites are primarily α6β2*-
nAChR, binding in IPN and medial habenula corresponds largely to α3β2*-nAChR sites
(Whiteaker et al., 2002). Variation in the β2VL genotype significantly affected the number
of [125I]-α-CtxMII binding sites revealed by the highly significant main effect of genotype
(F2,99 =250.5, p<0.001). The genotype effect was noted for regions in which the α6β2*-
nAChR sites predominate (Figure 3e, binding for HT mice was 69% of control and for MT
mice was 75% of control) as well as for the regions in which the α3β2*-nAChR sites
predominate (binding for HT mice was 74% of control and for MT mice was 71% of
control). However, the significant brain region by genotype interaction (F20,99 = 7.28,
p<0.001) indicates that the effect of β2VL genotype differed among the brain regions.
Subsequent one-way ANOVAs revealed that binding in the VTA and SN did not
significantly differ among the genotypes, while that in OT and onl of SC just failed to
achieve significance. The remaining seven regions showed statistically significant decreases
in [125I]-α-CtxMII binding sites.
3.1.5b. [125I]-α-CtxMII binding-Discussion: Introduction of the β2VL mutation caused
widespread reduction in [125I]-α-CtxMII binding. However, in contrast to the gene-dose
dependent reduction of binding observed for cytisine-sensitive [125I]-epibatidine binding,
the [125I]-α-CtxMII binding in MT mice (25% reduction) was comparable to that in HT
mice (31% reduction). This pattern was observed for the α3β2*-nAChR sites in medial
habenula and interpeduncular nucleus as well as the α6β2*-nAChR sites in the rest of the
brain (visual pathways and catecholaminergic sites). Although mRNA encoding the α6*
subunit is densely expressed in DA neuronal soma regions in the ventral tegmental area and
substantia nigra pars compacta, the density of α6*-nAChR in these regions is relatively
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small. More α6*-nAChR are found in the DA terminal regions, including the nucleus
accumbens and striatum, which may explain why differences are detected in the nucleus
accumbens but not in the ventral tegmental area or substantia nigra (Champtiaux et al.,
2003). It should be noted that the α6β2*-nAChR binding sites are complex and include
α6α4(β2)2β3-, (α6)2(β2)2β3- and perhaps some (α6)2(β2)3-nAChR subtypes (Gotti et al.,
2005; Grady et al., 2007). The effects of the β2VL mutation on these diverse subtypes,
individually, are unknown.
3.2. Effect of β2VL genotype on nAChR-mediated functional assays
Differences in β2VL genotype on nAChR function were assessed with several assays using
crude synaptosomal preparations. These assays measure presynaptic function of nAChRs by
either agonist-stimulated efflux of 86Rb+ (Gotti et al., 2008; Marks et al., 1999), release of
[3H]-GABA (McClure-Begley et al., 2009) or [3H]-dopamine (Grady et al., 1992; Salminen
et al., 2004).
3.2.1. The β2VL mutation decreased function measured by 86Rb+ Efflux
3.2.1a. ACh-stimulated 86Rb+ efflux-Results: 86Rb+ efflux experiments using
synaptosomes prepared from either cortex or thalamus of the mice differing in β2VL
genotype are illustrated in Figure 4. Agonist stimulated 86Rb+ efflux in both of these regions
are mediated predominantly by α4β2*-nAChR (Gotti et al., 2008; Marks et al., 2007; Marks
et al., 2000; Marks et al., 1999). The component of ACh-stimulated 86Rb+ efflux with high
sensitivity to stimulation by ACh (HS) activity in this assay is a result of activation of the
(α4β2)2(β2) and/or (α4β2)2(α5) stoichiometric forms of α4β2*-nAChR and the component
of ACh-stimulated 86Rb+ efflux with low sensitivity (LS) activity is mediated by activation
of the (α4β2)2(α4) form (Gotti et al., 2008). This determination is consistent with the
properties of α4β2-nAChR differing in subunit stoichiometry using heterologous expression
systems (Carbone et al., 2009; Moroni et al., 2006; Nelson et al., 2003; Zhou et al., 2003;
Zwart and Vijverberg, 1998).
The concentration effect curves for ACh stimulated 86Rb+ efflux were markedly different
for both thalamic and cortical samples prepared from WT, HT and MT mice (Figure 4a and
4d). The two-way ANOVA in thalamus (Figure 4a), revealed significant main effects of
genotype (F2,142=101.9, p<0.001) and ACh concentration (F6,142=16.59, p<0.001) as well as
a significant interaction of genotype with concentration (F12,142=3.64, p<0.001), confirming
the concentration dependence of the response, identifying a difference among the genotypes
and indicating genotype-determined change in the concentration effect curves. These results
were verified by the subsequent analysis of the effects of β2VL genotype on the parameters
for ACh-stimulated 86Rb+ efflux (maximum efflux Vmax and EC50). Both HS and LS Vmax
activity were significantly decreased in both HT and MT mice (Figure 4b, Vmax thalamus
HS, F2,6=14.95, p<0.01; Vmax thalamus LS, F2,6=20.63, p<0.01). EC50 values were also
significantly decreased in MT mice in both the HS and LS components (Figure 4c, EC50
thalamus HS, F2,6=10.59, p<0.01; EC50 thalamus LS, F2,6=5.80, p<0.05).
Similarly in the cortex (Figure 4d), there was a significant main effect of genotype
(F2,176=12.81, p<0.001) and concentration (F7,176=20.61, p<0.001), as well as a significant
genotype by dose interaction (F14,176=3.61, p<0.001). Subsequent analysis of the effects of
the β2VL mutation in cortex on HS and LS components of ACh stimulated 86Rb+ efflux
revealed a gene-dose dependent decrease in maximum efflux and EC50 for ACh for the LS
activity only (Figure 4e, Vmax cortex LS, F2,6=124.04, p=<0.001; Figure 4f, EC50cortex LS,
F2,6=18.63, p<0.01). The trend towards decreased HS activity was not statistically
significant.
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3.2.1b: Cytisine-sensitive [125I]-epibatidine binding in thalamus and cortex measures
predominantly the density of α4β2*-nAChR binding sites (Marks et al., 2007; Marks et al.,
2000). Thus, a direct comparison of the effect of the β2VL mutation on these sites in the
same samples of thalamus and cortex used for the functional assays could be made and
compared to the results determined autoradiographically. No significant differences in
binding Kd for [125I]-epibatidine were noted among mice differing in β2VL genotype for
these two regions. In cortex, WT mice had a Kd of 0.15±0.03 nM, HT values were
0.12±0.02 nM, and MT values were 0.13±0.02 nM. In the thalamus, Kd values were
0.15±0.06 nM for WT mice, 0.08±0.01 nM for HT mice, and 0.11±0.03 nM for MT mice.
Consistent with the autoradiographic results, there was a tendency for Bmax values to
decrease modestly as a consequence of the β2VL mutation. In the cortex, WT Bmax was
33.1±2.9 fmol/mg protein, HT was 32.7±1.7 fmol/mg protein and MT mice were 30.1±1.4
fmol/mg protein. Thalamus Bmax values were 96.1±12.2 fmol/mg protein for WT, 87.5±5.4
fmol/mg protein for HT, and 81.4±9.6 fmol/mg protein for MT mice.
3.2.1c. ACh-stimulated 86Rb+ efflux-Discussion: Overall, these data show that the β2VL
mutation increases the ACh sensitivity of α4β2*-nAChR mediated 86Rb+ efflux in the
thalamus and cortex of adult mice. However, it does not produce a significant gain in the
agonist response at any concentration. In fact, the mutation significantly reduces ACh-
stimulated efflux over a wide range of concentrations in thalamus and at concentrations near
the peak of concentration-response relation in the cortex. The reduced function does not
appear to result from a loss of receptor expression because there was no significant
reduction in maximum cytisine-sensitive [125I]-epibatadine binding. The observation of a
decreased response and higher sensitivity to agonists has been observed in several other
nAChR mice harboring subunits that display a gain of function in heterologous expression
systems, including α4 L9’S (Fonck et al., 2003), α4 L9’A (Fonck et al., 2005) and the
ADNFLE α4 S248F (Teper et al., 2007) mutants. This pattern of reduced function following
the introduction of mutations conferring increased sensitivity for agonist activation may be
the result of modification of receptor function to dampen down the effects of the high
activity receptors. Perhaps the mutation elicits a loss of surface receptor function, alters
subunit stoichiometry or causes retention of the receptors in the endoplasmic reticulum.
3.2.2. The β2VL mutation for steady-state decreased EC50 for activation of and
DC50 desensitization of 86Rb+ efflux by nicotine
3.2.2a. Nicotine-stimulated 86Rb+ efflux-Results: The β2VL mutation slows
desensitization of the nicotine response of α4β2- nAChRs expressed in HEK cells (De
Fusco et al., 2000). Therefore, we also measured stimulation of 86Rb+ efflux by nicotine and
nicotine-induced desensitization of ACh-stimulated 86Rb+ efflux (Figure 5). The effect of
the β2VL mutation on nicotine simulated 86Rb+ efflux is illustrated in Panels 5a and 5e. As
desensitization data is a percent of control value, the remaining panels in Figure 5 also
illustrate nicotine activation as percent of control.
Within the concentration range of nicotine used in this study, the concentration effect curves
for nicotine stimulated 86Rb+ efflux are adequately described as simple Michaelis-Menten
curves for both thalamus and cortex for all three β2VL genotypes. Analysis of the nicotine-
stimulated 86Rb+ efflux from thalamic synaptosomes (Figure 5a) by two-way ANOVA
revealed main effects of nicotine concentration (F7,72=121.48, p<0.001) and β2VL genotype
(F2,72=35.10, p<0.001), as well as a significant concentration by genotype interaction
(F14,72=8.50, p<0.01), results consistent with the increased efflux with increasing nicotine
concentration, differences among the genotypes and a difference in the concentration effect
curves among the genotypes. These results were confirmed by analysis of the fitted
parameters of the concentration effect curves. This analysis showed a significant decrease in
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maximal efflux between (F2,6=129.5, p<0.001) Significant differences between β2VL
genotypes were observed for Vmax (15.84±0.66 for WT, 13.44±0.31 for HT and 5.82±0.32
for MT; F2,6=129.5, p<0.001)and EC50 (1.63±0.37 μM for WT, 0.68±0.19 μM for HT and
0.25±0.04 μM for MT; F2,6=27.70, p<0.001).
Analysis of the nicotine-stimulated 86Rb+ efflux from cortical synaptosomes (Figure 5e) by
two-way ANOVA was similar to that obtained for thalamus with significant main effects of
nicotine concentration (F7,72=44.54, p<0.001) and β2VL genotype (F2,72=3.84, p<0.05), as
well as a significant concentration by genotype interaction (F14,72=2.09, p<0.05). Analysis
of the concentration-response relations showed significantly decreased Vmax as a function of
genotype (8.38±0.77 for WT, 6.54±0.44 for HT and 4.44±0.35 for MT; F2,6=38.48,
p<0.001), and significantly decreased EC50 (2.45±0.82 μM for WT, 0.58±0.18 μM for HT
and 0.38±0.15 μM for MT; F2,6=16.13, p<0.01). Note that the responses for nicotine-
stimulated 86Rb+ efflux are generally similar to those for ACh-stimulated 86Rb+ efflux
presented above: a shift to the left in EC50 values and a decrease in maximum 86Rb+ efflux
proceeding from WT to HT to MT.
3.2.2b. Desensitization of 86Rb+ efflux by nicotine-Results: We also used the 86Rb+ efflux
assay with cortical and thalamic synaptosomes to determine whether the β2VL mutation
alters steady-state desensitization of β2* nAChRs (Figure 5). Actual nicotine activation
curves are shown for thalamus (5a) and cortex (5e). The normalized activation and
desensitization curves calculated for WT mice are included in the panels for HT and MT
mice for direct comparison.
A nicotine concentration dependent decrease in ACh-stimulated 86Rb+ efflux was observed
for crude thalamic and cortical synaptosomes prepared from mice of all three genotypes.
Data shown are percent of control ACh-stimulated 86Rb+ efflux, with control values in the
thalamus 14.12±2.15 in WT, 6.08±0.96 in HT, and 4.29±0.52 in MT and control cortical
values 5.64±1.43 in WT, 3.35±0.47 in HT, and 3.19±0.37 in MT. Because of these
differences in control response, the two-way ANOVAs to evaluate the effects of genotype
and nicotine concentration were conducted on data normalized to control response. The two-
way ANOVA for thalamus revealed a main effect of nicotine concentration (F6,100=64.93,
p<0.001) and genotype (F2,100=5.95, p<0.01), but the concentration by genotype interaction
was not significant. Subsequent calculation of the DC50 concentrations in thalamus gave
values of 3.22±0.73 nM, 2.06±0.26 nM, and 1.14±0.30 nM for WT (Figure 5b), HT (5c),
and MT (5d) respectively. This significant gene dose dependent decrease in DC50 was
confirmed by subsequent one-way ANOVA (F2,6=14.3, p<0.01). Thus, the DC50 for HT was
1.6 fold lower and the DC50 for MT was 2.8-fold lower than the DC50 for WT. The two-way
ANOVA for cortex revealed a significant main effect of nicotine concentration
(F6,100=70.57, p<0.001) but neither a main effect of genotype or a genotype by
concentration interaction was noted. In the cortex, the DC50 values were 4.84±1.35 nM,
2.61±0.92 nM, and 1.76±0.71 nM for WT (5e), HT (5f), and MT (5g) mice respectively.
Analysis of the effect of genotype on DC50 values by one-way ANOVA indicated a
significant gene-dose dependent decrease (F2,6=7.18, p<0.05) with DC50 for HT 1.8 fold
lower and the DC50 for MT 2.6-fold lower than the DC50 for WT.
3.2.2c. Nicotine effects on 86Rb+ efflux-Discussion: Exposure of nAChR to low
concentrations of agonists desensitizes receptors (Katz and Thesleff, 1957; Marks et al.,
2010; Marks et al., 1996; Quick and Lester, 2002). Overall, the β2VL mutation resulted in a
progressive decrease in the DC50 for desensitization of ACh-stimulated 86Rb+ efflux by
exposure to low concentrations of nicotine. Similar gene-dose dependent leftward shifts in
both DC50 and EC50 for nicotine have been observed for α4β2*-nAChR harboring the
α4L9’A mutation when measured either for receptors heterologously expressed in Xenopus
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oocytes by electrophysiological methods or for thalamic and cortical synaptosomes
measured with 86Rb+ efflux (Fonck et al., 2005). Thus, introduction of either an α4 or a β2
gain of function mutation not only renders the resulting α4β2*-nAChR more sensitive to
agonist activation (decrease in EC50) but also more sensitive to steady-state desensitization
by exposure to sub-activating concentrations of agonists such as nicotine (lower DC50). For
the β2VL knock-in mouse model studied here, the tendency of the mutation to have a
greater effect on EC50 introduces a shift to the left for the area generating a larger
concentration range of smoldering activity (analogous to “window-current”)(Hoda et al.,
2008; Kuryatov et al., 2011) to a greater extent and at lower concentrations than for the WT.
3.2.3. The 2VL mutation altered ACh-stimulated [3H]-dopamine release—
Dopamine release is mediated by two subclasses of β2*-nAChRs, those with α6 subunits
and those without α6 subunits (Azam and McIntosh, 2005; Champtiaux et al., 2002; Drenan
et al., 2008; Quik et al., 2011). The α6β2*-nAChRs are inhibited by low concentrations of
α–CtxMII. α-CtxMII inhibition was used here to separate the activity mediated by α4β2*-
nAChR (α–CtxMII-resistant dose-concentration curves, Figure 6a) and α4β2*-nAChR (α–
CtxMII-sensitive dose-concentration curves, Figure 6b).
3.2.3a. [3H]-Dopamine release-Results: The two-way ANOVA for α–CtxMII-resistant DA
release revealed significant main effects of genotype (F2,168=9.31, p<0.001) and ACh
concentration (F7,168=119.70, p<0.001) as well as a significant genotype by concentration of
ACh interaction (F14,168=4.57, p<0.001). Subsequent analysis of the ACh concentration
response curves for the three genotypes demonstrated that the HT and MT had significantly
decreased α-CtxMII-resistant maximal release (Figure 6c, 14.03±0.53 for WT, 9.70±0.51
for HT and 8.35±0.76 for MT; F2,21=23.62, p<0.001), as well as lower EC50 values (Figure
6d, 0.91±0.15 μM for WT, 0.39±0.03 μM for HT and 0.26±0.12 μM for MT; F2,6=15.98,
p<0.01). The two-way ANOVA for α–CtxMII-sensitive DA release revealed a significant
main effect of ACh concentration (F7,168=18.06, p<0.001), but not of genotype
(F(2,168)=0.52, p>0.05); however, a significant interaction of genotype by concentration of
ACh was noted (F14,168=1.94, p<0.05). Subsequent analysis of the ACh concentration
response curves for the three genotypes demonstrated that the HT and MT had significantly
decreased α-CtxMII-sensitive maximal release (Figure 6c, 4.82±0.30 for WT, 3.31±0.30 for
HT and 3.73±0.29 for MT; F2,21=6.90, p<0.01) as well as lower EC50 values (Figure 6d,
0.30±0.13 μM for WT, 0.069±0.034 μM for HT and 0.065±0.029 μM for MT; F2,6=9.28,
p<0.05). The concentration response curves for ACh indicate a small gain-of-function at low
ACh concentrations for both subclasses of receptor with a decrease in release at higher
concentrations. K+-stimulated release (Figure 6e) was unaffected by the β2VL mutation
(F(2,9)=4.09, p>0.05).
3.2.3b. [3H]-Dopamine release-Discussion: Synaptosomal nAChR-evoked [3H]-dopamine
release is mediated by a diverse set of receptor subtypes, which can be generally classified
as those that are sensitive to inhibition by α-CtxMII (incorporating the α6 and β2 subunits:
(α6β2)(α4β2)β3, (α6β2)2β3 and possibly (α6β2)2(β2) and those that are resistant to
inhibition by α-Ctx MII (incorporating the α4 and β2 subunits: (α4β2)2(β2) and
(α4β2)2(α5) (Grady et al., 2007; Meyer et al., 2008; Salminen et al., 2007; Salminen et al.,
2004)). Both the α-CtxMII-sensitive and -resistant ACh-stimulated [3H]-dopamine release
from striatal synaptosomes are altered by the β2VL mutation. The response is somewhat
similar to that observed for 86Rb+ efflux: reduction of maximal response with a shift to the
left of the concentration-effect curves. However, the reduction in maximal response is not
gene-dose dependent in that the change observed for the MT is comparable to that for the
HT for both the α-CtxMII-sensitive and –resistant components. Perhaps the fact that a
significant fraction of both the α-CtxMII sensitive and the α-CtxMII-resistant activity is
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mediated by nAChR that include auxiliary subunits (β3 subunit or α5 subunit, respectively)
limits the extent of the functional decrease elicited by the β2VL mutation (Grady et al.,
2007; Salminen et al., 2004). The decrease in the α-CtxMII sensitive [3H]-dopamine release
(31% decrease in HT and 23% decrease in MT) is virtually identical to the decrease in
[125I]-α-CtxMII binding (31% decrease in HT and 25% decrease in MT), indicating that the
functional change arises predominantly from a decrease in the number of α6β2*-nAChR.
The effect of the β2VL substitution on the α-CtxMII-sensitive and -resistant components of
nAChR mediated [3H]-dopamine release differs from the effect of the α4S248F substitution
on these components (Teper et al., 2007). While the β2VL mutation reduced both the α-
CtxMII-sensitive and –resistant components of ACh stimulated [3H]-dopamine release, only
α-CtxMII-resistant release was affected by the α4S248F substitution (with both a decrease
in maximal release and a leftward shift of the concentration-response curve). The fact that
both α-CtxMII-sensitive and -resistant components of ACh-stimulated [3H]-dopamine
release require the β2 subunit, while only a subset of the α-CtxMII-sensitive component
requires the α4 subunit (α4β2)(α6β2)β3-nAChR) may explain the difference in the effect of
these two mutations (Grady et al., 2007; Salminen et al., 2004).
3.2.4. The β2VL mutation alters [3H]-GABA release—nAChR mediated ACh
stimulated [3H]-GABA release is mediated by α4β2*-nAChRs (McClure-Begley et al.,
2009). We chose to investigate the effects of the β2VL mutation on [3H]-GABA release in
cortex and hippocampus.
3.2.4a. [3H]-GABA release-Results: The results of the two-way ANOVA in the
hippocampus (Figure 7a) revealed a significant main effect of genotype (F2,133=7.73,
p<0.001) and a significant main effect of ACh concentration (F6,133=26.33, p<0.001), as
well a significant genotype by ACh concentration interaction (F12,133=1.893, p<0.05).
Subsequent analysis revealed that maximum ACh-stimulated [3H]-GABA release was not
significantly altered by genotype in hippocampus (Figure 7c, 1.96±0.17 for WT, 2.25±0.16
for HT and 2.11±0.14 for MT; F(2,6)=2.55, p>0.05), but significant differences in EC50
values were observed (Figure 7d,1.22±0.45 μM for WT, 0.50±0.17 for HT and 0.16±0.05
for MT; F2,6=24.47, p<0.001).
In cortex, (Figure 7b), there was a significant main effect of genotype (F2,133=14.44,
p<0.001) and of ACh concentration (F6,133=57.59, p<0.001), as well as a significant
genotype by ACh concentration interaction (F12,133=3.32, p<0.001). Subsequent analysis
revealed that maximum ACh-stimulated [3H]-GABA release, in contrast to hippocampus,
was significantly decreased in the cortex of MT mice (Figure 7c, 3.31±0.24 for WT,
3.69±0.19 for HT and 2.64±0.13 for MT; F(2,6)=22.99, p<0.01). A significant decrease in
EC50 values was observed (Figure 7d, 1.03±0.32 μM for WT, 0.39±0.12 for HT and
0.12±0.03 for MT; F2,6=41.84, p<0.001) by genotype in the cortex. There were no
significant differences among the genotypes in K+-stimulated GABA release (Figure 7e,
hippocampus F(2,18)=1.67, p>0.05; cortex F(2,20)=0.78, p>0.05).
The concentration response curves demonstrate that, at lower concentrations of ACh (below
1 μM in cortex and below 10 μM in hippocampus), as a result of the significant decreases in
EC50 values and modest changes in maximal responses, the β2VL mutation does produce a
considerable gain-of-function in hippocampus while at higher concentrations a mild
functional decrease is seen in cortex.
3.2.4b. [3H]-GABA release-Discussion: Much less reduction in maximal ACh-stimulated
[3H]-GABA release was seen (0% in hippocampus and 20% in cortex), in comparison
to 86Rb+ efflux and [3H]-dopamine release. In addition, the β2VL mutation resulted in a
decrease in EC50 of approximately 10-fold for the MT compared to WT. Consequently,
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distinct gain of function is observed for both HT and MT [3H]-GABA release upon
stimulation with ACh concentrations of 1 μM or lower. The retention of maximal nAChR
[3H]-GABA release in the HT and MT mice may be an adaptive consequence of increased
activity of the mutant receptors on excitatory neurons such that retained GABAergic
responses serve to dampen hyperexcitability. However, this retention of easily activated
nAChRs on presynaptic GABAergic terminals may also contribute to the hypersensitivity of
the HT and MT mice to nicotine-induced behaviors (Xu et al., 2011) through the
introduction of synchronization of inhibitory/excitatory neurons (Klaassen et al., 2006;
Mann and Mody, 2008; Steinlein, 2010; Zhang et al., 2012).
In contrast with the β2VL mutation (at the 22′ position of the M2 domain), the α4S248F
mutation (at the 6′ position of the M2 domain) resulted in significant decreases in maximal
ACh-stimulated [3H]-GABA release in HT (60% decrease) and MT (80% decrease), with a
30-fold decrease in EC50 (Teper et al., 2007). Even though a decrease in maximal release
was observed, the α4S248F HT and MT exhibited somewhat higher ACh-stimulated [3H]-
GABA release than WT at ACh concentrations below 1 μM. The fact that the mutations
were in different subunits (α4 versus β2) could be a cause of this differential response.
Alternatively, this difference in response to the mutations could reflect the fact that a
mutation at the 6′ position (further into the channel) has a greater impact on maximal
receptor function than a substitution at the 22′ position (near the opening of the channel).
Possibly, the change from the polar amino acid serine to a non-polar and bulkier
phenylalanine in the α4S248F mutation may have more impact on receptor function than the
more subtle change from valine to leucine in the β2VL mouse. It is possible that a
combination of the mutated subunit, the location of the mutation and the extent of structural
change of the substituted amino acid may influence whether GABA release exhibits an
overall gain of function, as with the β2VL mutation; or an overall loss of function, as with
the α4S248F mutation.
3.3. Behavioral assessment of the effect of nicotine treatment on β2VL mice
Acute injection of nicotine elicits a dose-dependent decrease in locomotor activity and an
induction of hypothermia in WT mice (Marks et al., 1985). β2 knock-out mice demonstrate
reduced sensitivity to the acute injections of nicotine on these measures (Tritto et al., 2004).
Mice expressing a gain of function mutation in the α4 nAChR subunit (α4L9’A) are more
sensitive to nicotine-induced hypothermia (Tapper et al., 2004). Furthermore, nicotine can
induce two types of seizures, both partial and generalized, in α4L9’A knock-in mice, but
only generalized seizures in WT animals (Fonck et al., 2005). Results from the
synaptosomal functional assays showed increased sensitivity to ACh and nicotine (decreases
in EC50 values) associated with the β2VL genotype. We utilized open field and Y-maze to
assess locomotor activity to further characterize nicotine sensitivity in β2VL mice. Doses
used for the activity/temperature measurements, as based on previous studies, did not
produce generalized seizures even in the MT mice (McCallum et al., 2006; Tritto et al.,
2004). We also evaluated the effects of higher nicotine doses on seizure activity and DAC
related behaviors.
3.3.1a. β2VL HT and MT mice are more sensitive to nicotine-induced
locomotor depression—Basal open field activity following saline injection was
significantly higher in MT compared to WT mice (inset, Figure 8a, F2,25=4.20, p<0.05).
Subsequently, the effect of nicotine treatment on locomotor activity is shown in Figure 8a as
a percent of each genotype’s saline-exposed control. Acute nicotine administration elicited
dose-dependent decreases in distance traveled in the open field for all three genotypes
indicated by the significant main effect of dose (F3,86=13.03, p<0.001). ED50 values were
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significantly lower for the HT (0.53±0.15 mg/kg) and MT mice (0.43±0.14 mg/kg)
compared to the WT (1.13±0.37 mg/kg) (F2,6=7.15, p<0.05).
No differences in basal Y-maze crosses were noted, so untransformed data were analyzed.
The effects of acute nicotine administration on Y-maze crosses showed significant main
effects of dose (F3,86=42.31, p<0.001) and genotype (F2,86=11.85, p<0.001), as well as a
significant interaction between dose and genotype (F6,86=2.23, p=0.05, Figure 8b). ED50
values for the HT (0.08±0.02 mg/kg) and MT (0.11±0.05 mg/kg) mice were significantly
lower than that for WT mice (0.34±0.09 mg/kg) (F2,6 = 18.85, p<0.01).
No differences in basal Y-maze rears following saline injection were noted, so
untransformed data were analyzed. The effects of acute nicotine treatment on Y-maze rears
showed significant main effects of dose (F3,86=29.50, p<0.001) and genotype; (F2,86=11.83,
p<0.001) (Figure 8c). ED50 values for the HT (0.07±0.03 mg/kg) and MT (0.06±0.02 mg/
kg) mice were significantly lower than that for WT mice (0.19±0.08 mg/kg (F2,6 = 7.25,
p<0.05).
3.3.1b. β2VL mice are more sensitive to nicotine-induced hypothermia—Mice
differing in β2VL genotype were also tested to determine if the mutation altered
thermoregulation in response to nicotine. We found that HT and MT mice were markedly
more susceptible to nicotine-induced hypothermia than WT mice (Figure 8d). Significant
main effects of nicotine on body temperature were noted for nicotine dose (F3,86=33.52,
p<0.001) and genotype (F2,86=34.30, p<0.001), as well as a significant dose by genotype
interaction (F6,86=3.94, p<0.01). Greater maximal temperature decreases were observed for
both HT and MT mice. The nicotine dose that elicited a temperature decrease of 2° C was
significantly lower for both HT (0.16±0.03 mg/kg) and MT (0.19±0.04 mg/kg) mice than for
WT mice (0.78±0.10 mg/kg) (F2,106 = 6.46, p<0.01).
3.3.1c. Nicotine effects on locomotion and body temperature-Discussion—
Both HT and MT mice were 2- to 4- fold more sensitive to acute nicotine administration
measured by depression of activity (Y-maze crosses and rears, and open field activity) and
body temperature. In WT mice, these responses are inhibited by mecamylamine, which
indicates that the behaviors are a consequence of nAChR activation, rather than
desensitization (Collins et al., 1986; Zambrano et al., 2009). No differences among the
genotypes on baseline (saline-injected) Y-maze crosses and rears and body temperature were
noted. However, saline-injected MT mice were significantly more active in the open field,
an observation that may reflect the higher home cage activity reported previously for MT
mice (Xu et al., 2011). The increased sensitivity to nicotine in the HT and MT mice
contrasts with decreased sensitivity measured for β2 knockout mice (Tritto et al., 2004) and
further confirms a role for β2*-nAChR as modulators of nicotine’s effects on these
measures. It is worth noting that although the magnitude differs, the leftward shift in
behavioral sensitivity (a 2.5- to 4.2-fold decrease in ED50), is similar to the leftward shift in
the concentration-response curves for nicotine-stimulated 86Rb+ efflux (6.5- to 10-fold). The
increased sensitivity may also arise from the increased smoldering functional activity
reflecting a balance of activation and desensitization of the α4β2*-nAChR. Thus, even
though there appears to be a tendency for loss of function of some β2*-nAChR, the
heightened agonist sensitivity of the remaining receptors may render the HT and MT mice
more sensitive to an acute agonist, in this case nicotine, challenge. The enhanced agonist
sensitivity may also reflect the retention of hyperactive GABAergic activity exhibited by HT
and MT mice. Another gain of function mutant (α4L9’A MT mice) is also much more
sensitive to nicotine-induced hypothermia demonstrating approximately a 20-fold shift in
ED50 (Tapper et al., 2007), indicating that insertion of a nAChR subunit with enhanced
affinity for nicotine increases sensitivity to nicotine mediated behaviors.
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3.3.2a. β2VL MT mice demonstrate a unique phenotype prior to EEG-
detectable nicotine-induced seizures—Cortical EEG recordings were performed to
determine whether nicotine-induced convulsion-like behaviors in β2VL mice were ictal
(true seizure) in nature. We observed distinct EEG/behavior patterns between β2VL MT and
WT littermates in response to nicotine. A single high dose (5mg/kg, i.p.) nicotine injection
in WT mice (n=4) led to a single tonic-clonic convulsion 3~4 min post-injection,
simultaneous with EEG spike-wave discharges (Figure 9a). When MT mice (n=5) were
injected with 5mg/kg nicotine, we observed two temporally separated convulsions: an initial
convulsion ~30 s after injection with forelimb clonus and loss of the righting response,
described further in DAC behavior described below, but with no EEG changes. A second
convulsion began 3–4 min after injection, was tonic-clonic, and had EEG spike-wave
activity, indicative of generalized seizure activity (Figure 9b).
3.3.2b. Nicotine induces DAC-related behaviors in mutant β2VL mice—Knock-
in mice bearing the α4S248F ADNFLE mutation display a novel behavioral response called
the dystonic arousal complex (DAC) following administration of 2 mg/kg nicotine (Teper et
al., 2007). The DAC response includes diagonal retrograde (Straub) tail, tonic forelimb
extension, tonic digit splaying, and occasionally forelimb clonus. Both the α4S28F (Tepper
and Lee, 2007) and β2VL ADNFLE mice display nicotine-induced, DAC-related behaviors,
which may be a manifestation of a phenotype exhibited by human ADNFLE patients. We
injected MT β2VL mice with 2 mg/kg nicotine to determine whether they displayed
responses similar to the α4S248F mice (Fig. 9c–f). Similar to the α4S248F mice, nicotine (2
mg/kg) reliably elicited diagonal retrograde tail, tonic forelimb extension, and tonic forelimb
digit splaying in MT mice but not WT littermates (Fig. 9c–f). All the MT mice displayed
diagonal retrograde tail (19/19 mice), almost all, tonic forelimb extension (18/19), and most,
tonic forelimb digit splaying (16/19). Most also exhibited forelimb clonus (12/19). In
contrast, only two WT mice displayed diagonal retrograde tail (2/19), a single WT mouse
displayed tonic forelimb extension and digit splaying (1/19), and none displayed forelimb
clonus (0/19). The typical sequence of these behaviors in the MT mice was diagonal
retrograde tail, followed by nearly simultaneous tonic forelimb extension and digit splaying,
and finally forelimb clonus. However, there were exceptions to this pattern. Some MT mice
displayed clonic forelimb movements that were interspersed with tonic limb extension and
occasionally preceded limb extension. The post-injection latencies for the onset of diagonal
retrograde tail, tonic forelimb extension, tonic digit splaying, and forelimb clonus in the
mutant mice were 31 ± 8 s (mean ± SEM, n = 19 mice), 57 ± 5 s (n = 17), 59 ± 6 s (n = 16),
and 59 ± 7 s (n = 12), respectively. Thus, the DAC response is a common feature of
α4S248F and β2VL mice.
3.3.2c. Nicotine effects on seizures and DAC-Discussion—Mice expressing the
β2VL mutation are not only more sensitive to the effects of nicotine, but at higher nicotine
doses (5 mg/kg), display behaviors not seen in WT mice reminiscent of human ADNFLE.
For example, MT mice receiving higher dose nicotine displayed forelimb clonus and loss of
righting response, reminiscent of repetitive jerky arm movements and asymmetrical
posturing seen in ADNFLE patients (Scheffer et al., 1995). Furthermore, during DAC
behaviors, the EEGs of β2VL mice are normal, which is also consistent with the observation
that a majority of ADNFLE patients present non-diagnostic EEGs (Combi et al., 2004;
Oldani et al., 1998; Rozycka and Trzeciak, 2003; Scheffer et al., 1995). Nicotine-induced
behavioral and electrographic patterns in β2VL mice are remarkably similar to other mutant
mice expressing ADNLFE mutations (Teper et al., 2007) or other gain-of-function mutations
in α4 or β2 nicotinic receptors, (Fonck et al., 2005) which taken together provide further
support to the hypothesis that ADNFLE is a disease of increased sensitivity of α4 or β2
nAChRs. The absence of EEG changes either in nicotine-treated β2VL mice and in
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ADNFLE patients experiencing convulsive behaviors may still represent partial or focal
seizures which are typically undetectable with cortical electrodes. Temporal separation of
behavioral patterns elicited by 5 mg/kg nicotine suggests the activation of distinct neuronal
circuits in β2VL mice, with DAC behaviors likely mediated by the activation of mutated
hypersensitive β2 -containing receptors.
Dopaminergic agonists such as apomorphine elicit Straub tail in mice (Zarrindast et al.,
1993). The β2VL mutation significantly enhances ACh-induced, a-CtxMII-resistant
dopamine release from striatal synaptosomes at 100 nM ACh (Figure 6a). Thus, an increase
in nicotine-induced dopamine release may contribute to the enhanced Straub tail response
displayed by β2VL MT mice. Tonic limb extension (posturing) and digit splaying are
associated with frontal lobe epilepsy in human patients and can be caused by ictal activity in
the supplementary motor cortex (Jobst and Williamson, 2005). These behavioral signs also
occur during human ADNFLE seizures (see Fig. 4b in (Scheffer et al., 1995)). Rodents do
not have a supplementary motor area (SMA) per se but the rostral forelimb area is thought to
be the anatomical equivalent of the SMA in the rodent cortex (Rouiller et al., 1993). Thus,
nicotine-induced activity in this area may underlie the tonic limb extension and digit
splaying observed in β2VL MT mice. In human frontal lobe epilepsy, limb clonus is
typically ascribed to ictal activity in the motor cortex (Jobst and Williamson, 2005). At
present, we do not know whether ADNFLE seizures are caused by a nAChR-mediated
process during early CNS development (Manfredi et al., 2009), acute activation of the
ADNFLE mutant nAChRs in the mature CNS, or a combination of both. However, the
appearance of behaviors such as tonic limb extension and digit splaying in nicotine-injected
ADNFLE mice suggests that acute activation of the mutant nAChRs could play a role in the
semiology of adult ADNFLE seizures.
4. Summary Discussion
Mouse models for ADNFLE clearly display “phenotypic differences” (Steinlein 2010). We
have provided further characterization for the β2 valine 287 leucine (β2VL) knock-in mouse
engineered by Xu et al (2011). Results support hypotheses of hyperactivity of GABAergic
neurons as a possible trigger for seizure-related activity (Klaassen et al, 2006; Mann and
Mody, 2008; Steinlein 2010). While the β2VL knock-in mouse model does not show the
typical seizures of ADNFLE seen in the transgene mouse model (Manfredi et al, 2009), the
behavioral phenotype does include sleep-wake disturbances (Xu et al, 2011), DAC activity
and increased sensitivity to nicotine (the latter two presented here). This regulation may
have a developmental component given that silencing transgene expression in the
overexpressing transgenic β2VL mouse during development prevents presentation of the
seizure phenotype (Manfredi et al., 2009).
This characterization of biochemical changes suggests some regulation of β2*-nAChR
expression and function occurs to reduce overstimulation in mice harboring the mutation.
The β2VL knock-in mutation elicits no change in mRNA expression, mild decreases in
mutant subunit protein, and somewhat larger decreases in receptor binding sites. Gene-dose
dependent decreases in EC50 values were noted for each of the functional assays. Any gain-
of-function seen at low agonist concentrations is likely attributable to a decrease in EC50.
However, a down regulation (decrease) in maximum activity was seen for a number of
nAChR responses measured biochemically. It could be postulated that these functional
decreases arise from the overstimulation of mutant nAChR and are an adaptive response to
that overstimulation, perhaps a consequence of negative feedback. The actual mechanisms
for the selective decreases in expression and function remain to be determined. Potential
mechanisms could include enhanced receptor retention in the endoplasmic reticulum,
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changes in subunit stoichiometry, and decreased receptor functionality (Srinivasan et al.,
2011;Son et al., 2009;Gentry and Lukas, 2002). Unlike the effects of other M2 mutations in
mice, the nAChR mediated [3H]-GABA release does not appear to be down regulated in the
β2VL mice.
The behavioral changes in the β2VL HT and MT mice are similar: the mice harboring the
mutation are more sensitive to acute nicotine administration than are WT mice. Although the
heightened sensitivity to nicotine seems inconsistent with a decrease in α4β2*–nAChR
function, the relative change in ED50 measured in vivo is similar to the change in EC50
measured in vitro. These data, in combination with similar assays for other gain-of-function
mutations, may lead to a better understanding of how such mutations in humans can result in
ADNFLE. It should be noted that significant changes were noted in the HT mice, which
more closely approximates human ADNFLE.
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Abbreviations
α-CtxMII α-conotoxin MII
CX Cortex
CX il, Cortex, inner layers
CX ol, Cortex, outer layers
DLG Dorsolateral geniculate
GP Globus pallidus
HP Hippocampus
IC Inferior colliculus
IC dc, Inferior colliculus, dorsal cortex
IPN Interpeduncular nucleus
MHb Medial habenula
NAcc Nucleus accumbens
OB Olfactory bulb
OT Olfactory tubercle
SC onl, Superior colliculus, optic nerve layer
SC sg, Superior colliculus, superficial grey
SN Substantia nigra
ST Striatum
TH Thalamus
TH av, Thalamus, anterioventral nucleus
TH lp, Thalamus, lateroposterior nucleus
TH vp, Thalamus, vetroposterior nucleus
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VLG Ventrolateral geniculate
VTA Ventral tegmental area
nAChR nicotinic acetylcholine receptor
ADNFLE autosomal nocturnal frontal lobe epilepsy
DAC Dystonic arousal complex
EEG Electroencephalogram
DFP Diisopropyfluorophosphate
SSC Saline sodium citrate
β2VL β2 nAChR subunits harboring a valine or leucine substitution at position 287
WT Mice harboring the wild-type amino acid (valine) at position 287) of the β2
nAChR subunit
HT Mice harboring one copy of the wild-type (valine) and one copy of the
mutant (leucine) at position 287 of the β2 nAChR subunit
MT Mice harboring the mutant amino acid (leucine) at position 287 of the β2
nAChR subunit
rtPCR reverse transcription polymerase chain reaction
ED50 Dose eliciting 50% of maximal response in vivo
EC50 Concentration eliciting 50% of maximal functional response in vitro
DC50 Concentration eliciting 50% decrease in response by desensitization
Vmax Maximal response for functional assays
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Highlights
• Mice with a leu to val mutation in the β2 nicotinic receptor subunit were
evaluated
• The mutation reduced β2 nicotinic receptor expression but not mRNA levels
• Mutant receptors were activated by lower concentrations of ACh or nicotine in
vitro
• The mutation had varying effects on maximal response
• Mutant and heterozygous mice were more sensitive to nicotine than wild-type
mice
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Figure 1. Genotype comparisons of the expression and agonist binding of receptors at the level of
the thalamus or striatum
Representative pseudocolor images for WT, HT and MT compare the effect of the β2VL
mutation at the level of the thalamus (approximately −1.6 mm Bregma) on mRNA levels of
β2 (row 1), mAb 270 labeling (row 2), total epibatidine binding sites (row 3), and cytisine-
resistant epibatidine binding (row 4), as well as on α-CtxMII binding in the level of the
striatum (approximately +1.0 mm Bregma) (row 5).
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Figure 2. Genotype comparisons of the expression and agonist binding of receptors at the level of
the IPN
Representative pseudocolor images for WT, HT and MT mice compare the effect of the
β2VL mutation at the level of the superior colliculus (approximately −3.5 mm Bregma) on
mRNA levels of β2 (row 1), mAb 270 labeling (row 2), total epibatidine binding (row 3),
cytisine-resistant epibatidine binding (row 4), and α-CtxMII binding (row 5.)
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Figure 3. Summary of changes in autoradiography data
Histograms present the overall effect of the β2VL mutation. Results have been normalized
to the binding measured for WT mice in each region (set to 100% for the individual regions)
and represent the mean ± SEM of the data for all brain regions listed in Tables 1–5. The
mutation did not alter β2 mRNA levels a), β2 protein levels measured by mAb270 were
significantly decreased in MT mice b), cytisine-sensitive epibatidine binding was
significantly decreased in both HT and MT mice (primarily representative of α4β2*-
nAChR) c), cytisine-resistant epibatidine binding was not significantly altered by the
mutation d), and α-CtxMII binding was significantly decreased in both HT and MT mice e).
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Figure 4. Decreased function of mutant α4β2* receptors in presynaptic nerve terminals, assessed
by 86Rb efflux in synaptosomes
ACh-stimulated 86Rb+ efflux was measured in crude synaptosomes prepared from cortex
and thalamus. The panels in the figures present: a) Concentration-response curves for 86Rb
efflux in thalamus. b) Maximal ACh stimulated 86Rb efflux for the higher ACh sensitivity
(HS, left) and lower ACh sensitivity components (LS, right) in thalamus c) EC50 values for
both HS and LS from thalamic synaptosomes of WT, HT and MT mice. d) Concentration-
response curves for 86Rb efflux in cortex. e) Maximal ACh stimulated 86Rb efflux for the
higher ACh sensitivity (left) and lower ACh sensitivity components (right) in the cortex, and
f) EC50 values for synaptosomes prepared from the cortex. (*, significantly different from
WT, p<0.05; +, significantly different from HT, p<0.05; n=4–9 per genotype and
concentration).
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Figure 5. β2VL mutation alters nicotine activation and steady-state desensitization, as assessed
in synaptosomes
Nicotine-stimulated 86Rb+ efflux and nicotine desensitization of ACh-stimulated 86Rb+
efflux were measured in crude thalamic and cortical synaptosomes. Concentration-response
curves comparing nicotine-stimulated 86Rb+ efflux for WT, HT and MT are shown for
thalamus a) and cortex e). Curves illustrating nicotine desensitization of ACh-
stimulated 86Rb+ efflux were compared to the curves for nicotine-stimulated 86Rb+ efflux
and are shown for WT thalamus b), cortex f), HT thalamus c), cortex g) and MT thalamus
d), cortex h). These curves have been normalized to maximal response in WT (15.84±0.66)
b), HT (13.44±0.31) c) or MT (5.82±0.32) d) thalamic synaptosomes. Dotted lines in c) and
d) show WT values for comparison. Desensitization and activation curves normalized to
maximal response in cortex for WT (7.70±1.22) f), HT (5.76±0.67) g) or MT (4.25±0.35) h)
cortical synaptosomes. Dotted lines in g) and h) show WT values for comparison. (Data are
mean ± SEM; n=2–9 mice per genotype and concentration).
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Figure 6. β2VL mutation alters ACh-mediated DA release from synaptosomes
Striatal synaptosomes from WT, HT, and MT β2VL mice were assayed for α-CtxMII-
resistant (α4β2*-nAChR-mediated) and -sensitive (α6β2*-nAChR-mediated) DA release
using ACh (0.01–30 μM). a) Concentration-response curve for DA release in striatal
synaptosomes that were α-CtxMII-resistant (non-α6β2*-containing) using ACh (0.01–30
μM). b) Concentration-response curve for DA release in a population of striatal
synaptosomes that were α-CtxMII-sensitive (α6β2*-containing) using ACh (0.01–30 μM).
c) Percent of WT maximum DA release for α-CtxMII-resistant (left) and α-CtxMII-
sensitive (right). d) EC50 values release for α-CtxMII-resistant (left) and α-CtxMII-sensitive
(right) populations from striatal synaptosomes e) K+-stimulated DA release in striatal
synaptosomes. Data are mean ± SEM,*, significantly different from WT, p<0.05; n=4 per
mice per genotype and concentration.
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Figure 7. β2VL mutation alters ACh-mediated GABA release from synaptosomes
Hippocampal and cortical synaptosomes from WT, HT, and MT β2VL mice were assayed
for ACh-mediated GABA release (0.03–30 μM ACh). a) Concentration-response curves for
hippocampal synaptosomes from WT, HT, and MT β2VL mice were assayed for ACh-
mediated GABA release (0.03–30 μM ACh). b) Concentration-response curves for cortical
synaptosomes from WT, HT, and MT β2VL mice were assayed for ACh-mediated GABA
release (0.03–30 μM ACh). c) Percent of WT maximum GABA release from hippocampal
and cortical synaptosomes d) EC50 values from hippocampal and cortical synaptosomes. e)
K+-stimulated GABA release in hippocampal and cortical synaptosomes. Data are mean ±
SEM, *, significantly different from WT, p<0.05; +, significantly different from HT,
p<0.05; n=6–8 per mice per genotype and concentration.
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Figure 8. Increased sensitivity to nicotine-induced behaviors in β2VL HT and MT mice
Mice from all three genotypes were injected with a single dose of nicotine (WT, 0, 0.5, 1.0
or 1.5 mg/kg; HT and MT 0, 0.125, 0.25, 0.5 or 1.0 mg/kg). Three min following injection,
mice were placed in the Y-maze and assessed for 3 minutes followed immediately thereafter
by a 5 min assessment in the open field to measure nicotine-induced locomotor activity. At
15 min post injection, rectal temperature was taken. In WT (black filled circles), HT (grey
filled circles) or MT mice (open circles), the effects of nicotine on measures of locomotion
measured in distance in the open field a), crosses b) and rears c) in the Y-maze test. d)
Effects of nicotine injection on body temperature, assessed 15 min after injection. Insets in
upper right corner of each panel show ED50 values for all three strain. By one-way
ANOVA, ED50 values were significantly decreased compared to WT values (data are mean
± SEM, *, p<0.05; **, p<0.01; n=4–9 per group).
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Figure 9. Seizure and DAC sensitivity in β2VL mice
a–b, Example EEG traces from WT and MT mice before and after a single nicotine injection
of 5 mg/kg, i.p.. Baseline EEG recordings were unremarkable in all mice tested. a) WT mice
dosed with 5 mg/kg nicotine (n=4) displayed spike-wave seizures (high amplitude activity
on EEG trace) that were accompanied by tonic-clonic convulsions. b) MT mice dosed with 5
mg/kg nicotine (n=5) displayed two distinct sets of behaviors: the first set starting with
Straub tail, forelimb clonus, and loss of righting response lasting 10 to 30 s, collectively
termed here as Dystonic Arousal Complex (DAC), which did not result in EEG
abnormalities, followed by, 2–3 min later, spike-wave seizure accompanied by tonic-clonic
convulsions. c–f, Nicotine-induced DAC behaviors following 2 mg/kg (i.p.) injections
including c) diagonal retrograde tail, d) tonic forelimb extension, e) forelimb digit splaying,
and f) forelimb clonus (c–f, data are mean ± SEM; n=12–18 mice).
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Table 1
In situ hybridization for β2 mRNA by brain region and genotype
Brain Region WT cpm/mg wet wt HT cpm/mg wet wt MT cpm/mg wet wt ANOVA Results
Cortex 1081 ± 30 1168 ± 23 1105 ± 102 F2,9= 0.51, p=0.62
Frontal cortex 932 ± 44 1067 ± 24 1002 ± 40 F2,9= 3.33, p=0.08
Olfactory bulbs 1262 ± 65 1569 ± 98 1255 ± 735 F2,9=0.17, p=0.84
Interpeduncular nucleus 2097 ± 149 2136 ± 86 2008 ± 449 F2,9= 0.05, p=0.94
Medial habenula 7654 ± 1012 6764 ± 712 6015 ± 735 F2,9= 0.97, p=0.41
Olfactory tubercles 805 ± 42 937 ± 44 1004 ± 64 F2,9= 3.94, p=0.06
Striatum 692 ± 44 756 ± 29 784 ± 60 F2,9=1.05, p=0.39
Dorsolateral geniculate 2406 ± 350 2737 ± 110 2374 ± 221 F2,9= 0.66, p=0.54
Medial geniculate 1871 ± 179 2065 ± 66 1671 ± 164 F2,9=1.84, p=0.21
Superior colliculus 1535 ± 174 1707 ± 39 1710 ± 234 F2,9= 0.34, p=0.72
Inferior colliculus, dorsal cortex 1717 ± 81 1625 ± 58 1547 ± 176 F2,9= 0.53, p=0.61
Thalamus 2079 ± 149 2376 ± 104 1882 ± 197 F2,9=2.58, p=0.13
Thalamus, anteroventral nucleus 2571 ± 156 2733 ± 118 2445 ± 303 F2,9= 0.48, p=0.63
Ventral tegmental area 2209 ± 116 2208 ± 45 2465 ± 368 F2,9= 0.44, p=0.66
Substantia nigra 1781 ± 46 1707 ± 138 1397 ± 108 F2,9=3.79, p=0.06
Data show in situ hybridization for [35S] β2 cRNA in mouse brain regions of all three β2VL genotypes. Hybridization was performed as described
in the methods section. Specific hybridization was quantitated utilizing standards of known activity and is represented in terms of cpm/mg wet wt.
Values are the mean ± SEM measured in four different mice.
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Table 2
β2 protein expression by region and genotype using mAb 270
Brain Region WT fmol/mg wet wt HT fmol/mg wet wt MT fmol/mg wet wt ANOVA Results
Cortex 1.02 ± 0.29 0.78 ± 0.18 0.56 ± 0.31 F2,9=0.75. p=0.50
Frontal cortex 1.38 ± 0.20 1.05 ± 0.20 0.86 ± 0.26 F2,9=1.47, p=0.28
Olfactory bulbs 0.66 ± 0.16 0.43 ± 0.16 0.49 ± 0.08 F2,9=0.74, p=0.50
Interpeduncular nucleus 4.56 ± 0.69 4.80 ± 0.33 4.07 ± 0.78 F2,9=0.35, p=0.72
Olfactory tubercles 0.76 ± 0.20 0.78 ± 0.20 0.46 ± 0.12 F2,9=1.02, p=0.40
Striatum 1.65 ± 0.23 1.50 ± 0.20 1.27 ± 0.21 F2,9=0.80, p=0.48
Medial geniculate 2.82 ± 0.18 3.40 ± 0.22 2.32 ± 0.30 F2,9=5.09, p=0.03*
Dorsolateral geniculate 4.77 ± 0.59 4.63 ± 0.33 3.50 ± 0.61 F2,9=1.76, p=0.23
Ventrolateral geniculate 3.72 ± 0.22 4.15 ± 0.33 3.24 ± 0.33 F2,9=2.36, p=0.15
Superior colliculus, optic nerve layer 3.00 ± 0.46 3.84 ± 0.39 3.42 ± 0.68 F2,9=0.10, p=0.90
Superior colliculus, superficial gray 3.72 ± 0.54 4.90 ± 0.54 4.32 ± 0.78 F2,9=0.88, p=0.45
Inferior colliculus, dorsal cortex 1.11 ± 0.15 1.56 ± 0.32 1.37 ± 0.46 F2,9=0.43, p=0.67
Thalamus 2.49 ± 0.36 2.93 ± 0.21 2.29 ± 0.33 F2,9=1.20, p=0.35
Thalamus, anteroventral nucleus 2.82 ± 0.26 2.95 ± 0.12 2.06 ± 0.37 F2,9=3.17, p=0.09
Trigeminal nucleus 1.91 ± 0.45 1.75 ± 0.12 1.45 ± 0.23 F2,9=0.60, p=0.57
Medial ventricular nucleus 1.03 ± 0.25 1.07 ± 0.20 0.87 ± 0.15 F2,9=0.27, p=0.77
β2 nAChR subunit protein levels were measured with binding of [125I]-mAb 270 as described in Methods. Binding was quantitated using [125I]-
standards of known activity and expressed as fmol/mg wet wt based on specific activity of the [125I]-mAb 270. Results are the mean ± SEM from
four individual mice per genotype. Regions with significant differences by one-way ANOVA are shown in bold type.
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Table 3
Cytisine-sensitive [125I]-epibatidine binding by region and genotype
Brain Region WT fmol/mg wet wt HT fmol/mg wet wt MT fmol/mg wet wt ANOVA Results
Cortex, inner layers 28.30 ± 4.77 23.40 ± 2.79 17.60 ± 3.62 F2,9= 1.96, p= 0.20
Cortex, outer layers 14.23 ± 4.20 10.15 ± 1.10 10.40 ± 3.40 F2,9= 0.52, p= 0.61
Frontal cortex 29.19 ± 4.93 24.62 ± 3.64 18.77 ± 4.91 F2,9= 1.32, p= 0.31
Interpeduncular nucleus 165.80 ± 17.30 198.90 ± 72.90 199.90 ± 3.50 F2,9= 0.20, p=0.82
Medial habenula 88.90 ± 11.40 136.20 ± 23.9 85.00 ± 35.2 F2,9=1.26, p=0.33
Olfactory tubercles 21.80 ± 5.30 14.20 ± 1.40 20.50 ± 7.40 F2,9= 0.58, p=0.58
Striatum 33.19 ± 6.50 27.40 ± 3.60 26.20 ± 6.40 F2,9=0.44, p=0.66
Dorsolateral geniculate 133.57 ± 32.52 90.30 ± 9.04 90.12 ± 23.00 F2,9=1.14, p=0.36
Ventrolateral geniculate 119.00 ± 25.10 107.00 ± 24.30 91.20 ± 19.40 F2,9=0.37, p=0.70
Superior colliculus, optic nerve layer 75.00 ± 11.50 64.60 ± 12.40 53.60 ± 6.60 F2,9=1.04, p=0.39
Superior colliculus, superficial gray 97.07 ± 22.71 67.15 ± 13.25 52.70 ± 8.27 F2,9=2.05, p=0.18
Inferior colliculus, dorsal cortex 32.80 ± 4.40 28.20 ± 6.70 20.30 ± 7.70 F2,9= 0.97, p= 0.42
Thalamus, ventroposterior nucleus 88.95 ± 10.18 75.87 ± 9.01 40.33 ± 6.99 F2,9= 8.12, p=0.01 **
Thalamus, anteroventral nucleus 129.13 ± 42.51 66.80 ± 9.74 35.76 ± 3.06 F2,9=3.57, p=0.07
Thalamus, lateroposterior nucleus 104.87 ± 15.52 77.75 ± 7.39 49.88 ± 5.38 F2,9= 7.00, p=0.01 **
Ventral tegmental area 54.10 ± 8.70 52.90 ± 8.10 42.20 ± 8.40 F2,9=0.61, p=0.57
Substantia nigra 50.00 ± 9.70 39.00 ± 4.90 33.80 ± 6.30 F2,9=1.30, p=0.32
Hypothalamus 18.70 ± 3.80 12.50 ± 1.90 6.90 ± 0.90 F2,9= 5.54, p=0.03 *
Globus pallidus 30.40 ± 9.20 18.70 ± 4.60 11.30 ± 2.70 F2,9=2.46, p=0.14
Hippocampus 17.40 ± 5.70 10.60 ± 3.60 7.70 ± 3.90 F2,9=1.23, p=0.34
Ventral tegmental geniculate 43.33 ± 9.40 28.73 ± 4.62 17.00 ± 2.94 F2,9=4.42, p= 0.05*
Cytisine-sensitive [125I] epibatidine binding (as a measure of α4β2-nAChR sites) was quantitated using [125I]-standards of known activity and
expressed as fmol/mg wet wt based on specific activity of the [125I]-epibatidine. Results are the mean ± SEM of binding from four individual mice
per genotype. Regions with significant differences by one-way ANOVA are shown in bold type.
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Table 4
Cytisine-resistant [125I]-epibatidine binding by region and genotype
Brain Region WT fmol/mg wet wt HT fmol/mg wet wt MT fmol/mg wet wt ANOVA Results
Interpeduncular nucleus 268.00 ± 55.00 242.00 ± 29.00 251.00 ± 82.00 F2,9=0.05, p= 0.95
Medial hahenula 275.00 ± 38.00 248.00 ± 25.00 322.00 ± 66.00 F2,9= 0.65, p=0.54
Striatum 1.76 ± 0.55 1.45 ± 0.22 1.36 ± 0.60 F2,9=0.19, p=0.83
Dorsolateral geniculate 18.00 ± 5.30 12.50 ± 2.10 11.90 ± 2.40 F2,9=0.89, p= 0.45
Superior colliculus, optic nerve layer 16.22 ± 5.30 9.42 ± 0.98 9.95 ± 1.95 F2,9=1.30, p=0.32
Superior colliculus, superficial gray 18.28 ± 1.98 21.00 ± 3.00 25.70 ± 4.20 F2,9= 1.38, p= 0.30
Inferior colliculus, dorsal cortex 13.40 ± 1.20 13.20 ± 1.40 18.80 ± 4.70 F2,9= 1.19, p= 0.35
Ventral tegmental area 3.90 ± 0.60 2.50 ± 0.70 3.80 ± 1.20 F2,9= 0.80, p= 0.48
Substantia nigra 3.90 ± 0.80 2.30 ± 1.00 3.80 ± 0.70 F2,9=1.13, p= 0.36
Cytisine-resistant [125I] epibatadine binding (primarily α3β4*-nAChR sites) was quantitated using [125I]-standards of known activity and
expressed as fmol/mg wet wt based on specific activity of the [125I]-epibatidine. Results are the mean ± SEM of binding from four individual mice
per genotype.
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Table 5
Quantitation of α-CtxMII-sensitive binding in eleven brain regions.
Brain Region WT fmol/mg wet wt HT fmol/mg wet wt MT fmol/mg wet wt ANOVA Results
Nucleus Accumbens 2.11 ± 0.08 1.34 ± 0.12 1.64 ± 0.03 F2,8=23.94, p=0.000***
Olfactory tubercles 0.98 ± 0.09 0.63 ± 0.09 0.67 ± 0.08 F2,7=4.38, p=0.06
Striatum 1.72 ± 0.07 1.12 ± 0.09 1.26 ± 0.05 F2,8=22.34, p=0.001***
Interpeduncular nucleus 2.69 ± 0.11 2.14 ± 0.15 1.86 ± 0.25 F2,7=6.78, p=0.02*
Medial habenula 2.35 ± 0.21 1.59 ± 0.17 1.69 ± 0.12 F2,8=5.97, p=0.03*
Dorsolateral geniculate 4.11 ± 0.27 2.82 ± 0.18 2.77 ± 0.16 F2,8=13.05, p=0.003**
Ventrolateral geniculate 4.13 ± 0.33 2.97 ± 0.17 2.91 ± 0.15 F2,8=8.38, p=0.011*
Superior colliculus, optic nerve layer 2.94 ± 0.28 2.01 ± 0.23 2.16 ± 0.21 F2,8=3.99, p=0.06
Superior colliculus, superficial gray 3.95 ± 0.17 2.98 ± 0.37 2.99 ± 0.05 F2,8=7.966, p=0.01*
Ventral tegmental area 0.97 ± 0.08 0.64 ± 0.07 0.78 ± 0.11 F2,8=2.82, p=0.12
Substantia nigra 0.78 ± 0.04 0.56 ± 0.03 0.67 ± 0.09 F2,8=2.73, p=0.13
The effect of the β2VL mutation on α6β2*-nAChR and α3β2*-nAChR sites was measured autoradiographically using [125I]-α-CtxMII binding
which was quantitated using [125I]-standards of known activity and expressed as fmol/mg wet wt based on specific activity of the [125I]-α-
CtxMII. Results are the mean ± SEM of binding levels from four individual mice per genotype. Regions with significant differences by one-way
ANOVA are shown in bold type.
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